News
The Journal “suPAR News” No. 3, 2020 about suPAR and COVID-19 is out – read it here!
June 25, 2020: Read the Journal “suPAR News” No. 3, 2020 – with lots of interesting articles and interviews regarding suPAR and COVID-19 from around the world! […]
Clinical Implementation of suPARnostic®TurbiLatex in routine use at The Cartagena University Hospital in Spain
suPARnostic® TurbiLatex will now be available for clinical decision making in the Emergency Department of Hospital General Universitario Santa Lucía in Cartagena, Spain. […]
suPARnostic® TurbiLatex now CE/IVD approved for the Abbott Architect Chemical Diagnostic instruments
ViroGates announces that it has completed the development and regulatory approval (CE-IVD) of its suPARnostic® TurbiLatex product for the for the Abbott Architect 4000, 8000 and 16000 platform, which allows for clinical use of suPARnostic® TurbiLatex on the Abbott Architect [...]
suPAR is a Risk Marker for Kidney Disease in Acute Medical Patients
New study showing that elevated suPAR is an independent risk marker for incident chronic and acute kidney disease in acute medical patients, is published in Frontiers in Cell and Developmental Biology by Iversen E. et al. […]
6.6 DKKm EU Horizon 2020 grant to support better risk stratification of COVID-19 patients with suPARnostic® in the ED
ViroGates is awarded a 6.6 DKKm EU Horizon 2020 grant for a project to optimize hospital ressources and ensure early therapeutic intervention for COVID‐19 patients based on suPARnostic®. The grant will support the efforts of better clinical risk stratification of [...]
suPAR and prediction of Acute Kidney Injury in New England Journal of Medicine
In today’s New England Journal of Medicine, Danish scientists show that patients presenting in the Emergency Department with elevated suPAR (> 4.3 ng/ml, top quartile) have 23 times higher risk for development of kidney failure compared to those with low [...]